In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Best of the Blog: IN VIVO, August 2008

Executive Summary

A better way to do risk-benefit: FDA is seeking a 'more formalized and comprehensive approach to the benefit/risk assessment.' Though there is obvious appeal for such a tool, but here's why it isn't going to workout as planned.
Advertisement

Related Content

The Value Proposition: Why Pharma Should Embrace Comparative Effectiveness
The Value Proposition: Why Pharma Should Embrace Comparative Effectiveness

Topics

Advertisement
UsernamePublicRestriction

Register

IV003162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel